Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 10/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SIK1 | P57059 | 2/20 | 0.41 |
| ▸ | SIK2 | Q9H0K1 | 2/20 | 0.41 |
| ▸ | SIK3 | Q9Y2K2 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2646226 | 0.88 | FGFR1 (0.47) | FGFR1MEN1KMT2ASIK1SIK2 | |
| SCHEMBL2652319 | 0.86 | FGFR1 (0.44) | FGFR1MEN1KMT2ASIK1SIK2 | |
| SCHEMBL2662575 | 0.85 | FGFR1 (0.45) | FGFR1HPGDMAPK1SMN1; SMN2KIT | |
| SCHEMBL2654499 | 0.84 | FGFR1 (0.51) | FGFR1MEN1KMT2ASIK1SIK2 | |
| SCHEMBL2648767 | 0.81 | MEN1 (0.48) | FGFR1MEN1KMT2ASIK1SIK2 | |
| SCHEMBL2655309 | 0.81 | FGFR1 (0.44) | FGFR1MAPK1SMN1; SMN2KITFLT3 | |
| SCHEMBL2659773 | 0.81 | FGFR1 (0.42) | FGFR1MEN1KMT2AHPGDMAPK1 | |
| SCHEMBL2654436 | 0.80 | FGFR1 (0.41) | FGFR1MEN1KMT2ASIK1SIK2 | |
| SCHEMBL2655671 | 0.79 | FGFR1 (0.43) | FGFR1HPGDALDH1A1 | |
| SCHEMBL2653433 | 0.79 | NT5E (0.41) | FGFR1HPGDMAPK1SMN1; SMN2KIT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | NEUROSEARCH A/S (DK) | 2006-03-30 | — | — | US | disclosed |
| EP-1613618-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA- sb A /sb RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2006-01-11 | — | — | EP | disclosed |
| WO-2004087690-A2 | BENZIMIDAZOLE DERIVATIVES AND THEIR USE FOR MODULATING THE GABA-A RECEPTOR COMPLEX | NEUROSEARCH A/S (DK) | 2004-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069135-A1 | Benzimidazole derivatives and their use for modulating the gaba-a receptor complex | GABRB2, GABRB1, GABRB3 | FGFR1 3374/4885MEN1 4428/4885KMT2A 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.